Research Topics
Genomes and Genes
| Charles LuSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Suspected spinal cord compression in cancer patients: a multidisciplinary risk assessmentCharles Lu
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
J Support Oncol 3:305-12. 2005..These predictors may help clinicians to assess risk in this patient population...- Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancerXin Lin
Departments of Epidemiology and Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1155 Pressler Boulevard, Houston, TX 77030, USA
Clin Cancer Res 12:5720-5. 2006..We hypothesized that the expression of these genes would have significant predictive value for cancer development and prognosis... 
Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropeniaLinda S Elting
Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 447, Houston, TX 77030, USA
J Clin Oncol 26:606-11. 2008..We retrospectively compared the outcomes and costs of outpatient and inpatient management of low-risk outpatients who presented to an emergency department with febrile neutropenia (FN)...
Human papillomavirus and survival of patients with oropharyngeal cancerK Kian Ang
University of Texas M D Anderson Cancer Center, Houston, USA
N Engl J Med 363:24-35. 2010..Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown...- Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humansCharles Lu
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
PLoS ONE 7:e34833. 2012..No drug strategies currently exist targeting loss-of-function genetic abnormalities. We report the first in-human systemic gene therapy clinical trial of tumor suppressor gene TUSC2... - Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinomaCharles Lu
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 106:441-7. 2006.... - Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trialCharles Lu
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030 4009, USA
J Natl Cancer Inst 102:859-65. 2010..CONCLUSIONS The addition of AE-941 to chemoradiotherapy did not improve overall survival in patients with unresectable stage III NSCLC. This study does not support the use of shark cartilage-derived products as therapy for lung cancer... - Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markersCharles Lu
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
J Clin Oncol 22:4575-83. 2004.... - Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapyXifeng Wu
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1340, Houston, TX 77030, USA
J Natl Cancer Inst 103:817-25. 2011..Interindividual variation in genetic background may influence the response to chemotherapy and overall survival for patients with advanced-stage non-small cell lung cancer (NSCLC)... - Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancerMichelle A T Hildebrandt
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
PLoS ONE 5:e12402. 2010..These results suggest that genetic variations among inflammation pathway genes may modulate the development of radiation-induced toxicity and, ultimately, help in identifying patients who are at an increased likelihood for such events... - Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapyXifeng Wu
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Pharmacogenet Genomics 18:955-65. 2008..Therefore, we applied a pathway-based approach to evaluate the cumulative effect of multiple polymorphisms on clinical outcome of patients with non-small cell lung cancer... - Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancerSamir Sejpal
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer 117:3004-13. 2011..We hypothesized that proton beam therapy for most patients with NSCLC could permit higher tumor doses with less normal-tissue toxicity than photon RT delivered as 3-dimensional conformal RT (3D-CRT) or intensity-modulated RT (IMRT)... - High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapyJoe Y Chang
Department of Radiation Oncology, Epidemiology, and Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 11:2894-8. 2005.... - PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapyXia Pu
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Lung Cancer 71:82-8. 2011..With further validation, our findings may provide additional biomarkers for customized treatment of platinum-based chemotherapy for NSCLC... - Genetic variants in cell cycle control pathway confer susceptibility to lung cancerWei Wang
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 13:5974-81. 2007..To test the hypothesis that common sequence variants of cell cycle control genes may affect lung cancer predisposition... - Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer centerCharles S Cleeland
The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 29:2859-65. 2011..We compared risk factors for high disease- and treatment-related symptom burden over 15 weeks of therapy in medically underserved patients with advanced non-small-cell lung cancer and in patients treated at a tertiary cancer center... - Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trialRitsuko Komaki
Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 58:1369-77. 2004..To determine the ability of amifostine to reduce the severity and/or incidence of the acute toxicities of concurrent chemotherapy and radiotherapy (RT) for non-small-cell lung cancer... - Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancerJingyao Dai
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
PLoS ONE 6:e21120. 2011..To our knowledge, this is the first study to reveal the importance of RGS gene family in the survival of late-stage NSCLC patients... - ATM sequence variants associate with susceptibility to non-small cell lung cancerHushan Yang
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX
Int J Cancer 121:2254-9. 2007.... - Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancerMoubin Lin
Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Carcinogenesis 32:1050-6. 2011..These results suggest that genetic variations in the TGF-β pathway are potential predictors of overall survival in NSCLC patients treated with platinum-based chemotherapy with or without radiation... - Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancerJoe Y Chang
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
Cancer 117:4707-13. 2011..They report early results of a phase 2 study of high-dose proton therapy and concurrent chemotherapy in terms of toxicity, failure patterns, and survival... - Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancerJian Gu
Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 12:7329-38. 2006..0007). CONCLUSION: Hypermethylation of multiple genes exhibited significant differential effect on NSCLC patient survival. Assessment of the effect of each methylated gene on survival is needed to provide optimal prognostic value... - Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancerJikai Yin
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77030, USA
Carcinogenesis 32:1867-71. 2011..These results suggest that genetic variations in cell cycle pathway genes may affect the survival of patients with stages III-IV NSCLC individually and jointly... - Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysisJinliang Xing
Department of Epidemiology, Unit 1340, The University of Texas M D Anderson Cancer Center, 1155 Pressler Boulevard, Houston, TX 77030, USA
Cancer Epidemiol Biomarkers Prev 16:1517-22. 2007..Additionally, cell accumulation indices at both G2-M and S phases were not associated with clinical stages. We conclude that attenuated functions of G2-M and S cell cycle checkpoints might be susceptibility markers for lung cancer... - Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)Hai T Tran
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030, USA
Invest New Drugs 29:499-505. 2011..To assess the pharmacokinetics and evaluate potential drug-drug interactions between erlotinib, paclitaxel and carboplatin... - Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer riskJie Lin
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Carcinogenesis 33:1699-706. 2012..Future studies are needed to identify the causal SNPs and elucidate the underlying molecular mechanisms... - A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancerCharles Lu
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 9:2085-91. 2003..The outcome of a recently closed Cancer and Leukemia Group B Phase II study of similar design (CLB-39808) should help determine whether or not this approach warrants testing in a randomized setting... - Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experienceZhi Qin Jiang
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Int J Radiat Oncol Biol Phys 83:332-9. 2012..In 2007, we published our initial experience in treating inoperable non-small-cell lung cancer (NSCLC) with intensity-modulated radiation therapy (IMRT). The current report is an update of that experience with long-term follow-up... - Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom InventoryTito R Mendoza
Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, Texas 77030, USA
Oncologist 16:217-27. 2011.... - Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumorsHai T Tran
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
Cancer Chemother Pharmacol 54:308-14. 2004..The present study was designed to determine the toxicity and pharmacokinetics of carboplatin in combination with TNP-470 in comparison with the doublet regimen of paclitaxel and carboplatin in patients with solid tumors... - Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancerGeorge R Blumenschein
Department of Thoracic and Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Invest New Drugs 26:81-7. 2008..Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients... - Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesotheliomaCharles Lu
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
J Clin Oncol 23:3495-501. 2005..The optimal role of intrapleural L-NDDP therapy currently remains to be determined... - Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancerJie Wang
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 10:6119-25. 2004.... - Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer riskMatthew B Schabath
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Am J Epidemiol 161:412-22. 2005..19, 0.66) protective genotypes as compared with none (OR = 0.69, 95% CI: 0.30, 1.59). The biologic role of respiratory disease in lung cancer is unclear. Further study may yield new insights for identification of susceptible subgroups... - Initial medical attention on patients with early-stage non-small cell lung cancerXing Chen
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
PLoS ONE 7:e32644. 2012..Understanding the reasons that caused initial detection of these patients is important for early diagnosis. However, these reasons are not well studied... - The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapyRoy S Herbst
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 95:340-53. 2002..The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously treated patients with Stage IIIB (with pleural effusion) or Stage IV NSCLC... - Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in CaucasiansJian Gu
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Mutat Res 581:97-104. 2005..02). Our data suggest that having a NAT2 slow acetylator genotype is a significant risk factor for BC, particularly in smokers and older individuals... - Pharmacogenetics in esophageal cancerXifeng Wu
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
Semin Oncol 32:S87-9. 2005..This emergent area of biomedicine could lead to substantially improved clinical outcomes for patients with adenocarcinoma or squamous cell carcinoma of the esophagus... - Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancerXin Shelley Wang
Department of Symptom Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer 116:137-45. 2010..However, translating patient-reported outcomes into useful prognostic information for individual patients has been problematic... - Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumorsFadlo R Khuri
Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
Clin Cancer Res 10:2968-76. 2004.... - Genome sequence of Theileria parva, a bovine pathogen that transforms lymphocytesMalcolm J Gardner
Institute for Genomic Research TIGR, 9712 Medical Center Drive, Rockville, MD 20850, USA
Science 309:134-7. 2005..Several biosynthetic pathways are incomplete or absent, suggesting substantial metabolic dependence on the host cell. One protein family that may generate parasite antigenic diversity is not telomere-associated... - Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in CaucasiansJian Gu
Department of Epidemiology, The University of Texas M D Anderson Cancer Center Houston, TX 77030, USA
Carcinogenesis 28:350-5. 2007..45% of controls) exhibited a reduced lung cancer risk (OR=0.78, 95% CI=0.63-0.97). This is the first epidemiological study to report significant associations between STK15 polymorphisms and lung cancer risk...